Innate Pharma : Innate Pharma to return Lumoxiti commercialisation rights to AstraZeneca
>Innate to return commercialisation rights of Lumoxiti - Innate Pharma today announced that it will return the US and EU commercialisation rights of Lumoxiti, a drug approved by the FDA for certain patients with relapsed or refractory hairy cell leukaemia (a rare blood disease). To this end, the company has announced 1/ it will develop a transition plan, including costs and transfer timeline of the US marketing and distribution rights of Lumoxiti back to AstraZ...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.